首页> 外文OA文献 >Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan

【2h】

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan

机译：非小型细胞肺癌患者的临床结果，使用PEMBROLIZUABAb作为一线治疗治疗的编程死亡配体-1的超高表达：日本回顾性多中心队列研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ryuya Edahiro; Masaki Kanazu; Hiroyuki Kurebe; Masahide Mori; Daichi Fujimoto; Yoshihiko Taniguchi; Hidekazu Suzuki; Katsuya Hirano; Toshihide Yokoyama; Mitsunori Morita; Yasushi Fukuda; Junji Uchida; Takeshi Makio; Motohiro Tamiya;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study [J] . Kawachi Hayato, Tamiya Motohiro, Tamiya Akihiro, Ecological restoration . 2020,第1期

机译：高PD-L1表达的先进非小细胞肺癌转移位点和第一线Pembrolizumab治疗结果的关联：回顾性多中心队列研究
2. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) [J] . Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, Investigational new drugs. . 2019,第6期

机译：Pembrolizumab作为先进非小细胞肺癌的一线治疗的疗效和安全性，具有至少50％PD-L1积极性：多中心回顾性队列研究（Hope-001）
3. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study [J] . Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, BMC Cancer . 2021,第1期

机译：与较短的耐用反应相关的临床因素，以及对PD-L1阳性非小细胞肺癌患者的第一线Pembrolizumab单药治疗的抗性模式：回顾性多中心研究
4. A proteomic signature of relapse-related death predicting clinical outcome in human non-small cell lung cancer [C] . Kiyoshi Yanagisawa M.D., Shuta Tomida, Yukako Shimada, ASMS Conference on Mass Spectrometry and Allied Topics . 2006

机译：复发相关死亡的蛋白质组学特征预测人非小细胞肺癌临床结果
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan [O] . Ryuya Edahiro, Masaki Kanazu, Hiroyuki Kurebe, 2012

机译：使用派姆单抗作为一线治疗的非小细胞肺癌患者具有程序化死亡配体1超高表达的临床结局：日本多中心回顾性队列研究
7. Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study [O] . Dong Hyeon Lee, Jae Yong Jeong, Wan Song 2021

机译：编程死亡配体-1对肿瘤浸润性免疫细胞对肌肉侵袭性膀胱切除术治疗的患者肿瘤浸润免疫细胞表达的预后价值：肌肉侵袭性膀胱癌：回顾性队列研究

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan

著录项

引文网络

相似文献

相关主题

期刊订阅